Compounds > paclitaxel
Page last updated: 2024-08-23

paclitaxel and Cancer of the Urinary Tract

paclitaxel has been researched along with Cancer of the Urinary Tract in 68 studies

Research

Studies (68)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (13.24)18.2507
2000's28 (41.18)29.6817
2010's28 (41.18)24.3611
2020's3 (4.41)2.80

Authors

AuthorsStudies
Bajorin, D; Bellmunt, J; Enokida, H; Frenkl, T; Fujimoto, K; Fukasawa, S; Imai, K; Nishimura, K; Nishiyama, H; Perini, R; Sassa, N; Shimamoto, T; Takahashi, K; Tanaka, Y; Yamamoto, Y; Yokoyama, M1
Fukui, I; Inoue, T; Masuda, H; Numao, N; Ogawa, M; Yamamoto, S; Yonese, J; Yuasa, T1
Arcangeli, M; Baldari, B; D'Errico, S; Fineschi, V; Frati, P; Santurro, A1
Alexander, L; Bahl, A; Birtle, A; Chakraborti, P; Crabb, SJ; Dixon-Hughes, J; Huddart, RA; Hussain, SA; Jagdev, S; Jones, RJ; Kelly, C; Morris, A; Paul, J; Powles, T; Protheroe, AS; Stobo, J; Stockdale, A; Sundar, S1
Kelly, C; Paul, J; Powles, T; Stobo, J1
Horiguchi, M; Uno, H; Wei, LJ1
Ebara, S; Edamura, K; Hanamoto, M; Hayashi, N; Hirata, T; Ogura, K; Saika, T; Takamura, K1
Iguchi, T; Kato, M; Kuratsukuri, K; Nakatani, T; Nishihara, C; Takeyama, Y; Tamada, S; Yamasaki, T1
Chen, C; Meng, X; Qin, Z; Song, N; Wang, Y; Xia, J; Xu, L; Zhang, Q; Zhou, X1
Chi, KN; Eigl, BJ; Forbes, C; Parimi, S; Tsang, ES1
Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Frenkl, TL; Gerritsen, W; Gurney, H; Lee, JL; Nam, K; Necchi, A; Perini, RF; Petrylak, DP; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ1
Alva, A; Daignault, S; Hussain, M; Smith, DC1
Goto, Y; Kato, H; Matano, Y; Nishino, A; Tsukayama, S; Yoshimitsu, M1
Lee, JL; Park, JH1
Bellmunt, J; Choueiri, TK; Di Lorenzo, G; Federico, P; Mullane, S; Necchi, A; Pond, GR; Qu, AQ; Rosenberg, JE; Sonpavde, G1
Albers, P; Balabanov, S; Bögemann, M; Gschwend, J; Hartmann, A; Honecker, F; Niegisch, G; Ohlmann, CH; Ohmann, C; Retz, M; Stöckle, M; Thalgott, M; Vom Dorp, F1
Albers, P; Bellmunt, J; Buonerba, C; Choueiri, TK; Di Lorenzo, G; Kitamura, H; Kume, H; Lee, JL; Matsumoto, K; Mullane, S; Necchi, A; Niegisch, G; Pond, GR; Rozzi, A; Sonpavde, G1
Campbell, MT; Carolla, RL; Harris, DR; Munsell, MF; Pagliaro, LC; Siefker-Radtke, AO1
Albers, P; Niegisch, G; Retz, M; Siener, R1
Fan, A; Haas, D; Harshman, L; Lam, A; Li, S; Narayanan, S; Pachynski, R; Poushnejad, S; Srinivas, S; Vaishampayan, U1
Bajorin, DF; Bellmunt, J; Choueiri, TK; Climent, MA; Culine, S; de Wit, R; Fong, L; Fradet, Y; Gerritsen, W; Gurney, H; Lee, JL; Mai, Y; Necchi, A; Perini, RF; Petrylak, DP; Poehlein, CH; Quinn, DI; Sternberg, CN; Vaughn, DJ; Vogelzang, NJ1
Cheng, T1
Becker, A; Bolenz, C; Gabriel, U; Herrmann, E; Michel, MS; Steidler, A; Trojan, L; Weiss, C; Wenzel, M1
Bordin, F; De Marco, F; Di Nicola, S; Lanzetta, G; Rozzi, A; Salerno, M1
Akino, H; Aoki, Y; Ito, H; Miwa, Y; Oyama, N; Yokoyama, O1
Albers, P; Fimmers, R; Niegisch, G; Park, SI; Siener, R1
Baba, S; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K1
Culine, S; Demery, ME; Pouessel, D; Thézenas, S1
Ahn, H; Ahn, JH; Ahn, S; Hong, JH; Kim, CS; Kwon, JH; Lee, JL; Lim, HY; Park, SH; Song, C1
Bellmunt, J; Boehle, A; Chevreau, C; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Laufman, LR; Marreaud, S; Mead, GM; Paz-Ares, L; Raghavan, D; Skoneczna, I; Sylvester, R; von der Maase, H; Winquist, E1
Hoshina, A; Onishi, T; Sasaki, T1
Kanetake, H; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sagara, Y; Sakai, H1
Assaf, E; Bouaita, L; Culine, S; Delbaldo, C; Pouessel, D; Sellam, Z; Verlinde-Carvalho, M1
Logothetis, C; Millikan, R1
Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L1
Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP1
Dreicer, R; George, CS; Manola, J; Roth, BJ; Schneider, DJ; Schwerkoske, JF; Wilding, G1
Dawson, NA; Edelman, MJ; Houston, J; Lara, PN; Lauder, I; Law, LY; Meyers, FJ1
Dreicer, R; Edelman, MJ; Hudes, GR; Kuross, S; Manola, J; Roth, BJ; See, WA; Wilding, G1
Demura, T; Harabayashi, T; Ishikawa, R; Koyanagi, T; Mitsuhashi, K; Murakumo, M; Seki, H; Shinohara, N; Suzuki, S; Toyota, H1
Asmar, L; Dakhil, S; Friedland, DM; Gregurich, MA; Hollen, C1
Mikami, K; Miki, T; Mizutani, Y1
Hinke, A; Johannsen, M; Loening, SA; Roigas, J; Sachs, M; Schnorr, D; Staack, A; Wille, AH1
Amsellem-Ouazana, D; Beuzeboc, P; Oudard, S; Peyromaure, M; Scotté, F; Vieillefond, A1
Crawford, ED; Faulkner, JR; Keiser, WL; Petrylak, DP; Redman, BG; Small, EJ; Vaishampayan, UN1
Demura, T; Harabayashi, T; Matsuyama, H; Mitsuhashi, K; Murakumo, M; Nagamori, S; Nagao, K; Naito, K; Nonomura, K; Seki, H; Shinohara, N; Suzuki, S1
Habuchi, T; Higashi, S; Itoh, N; Kamoto, T; Kinoshita, H; Nakamura, E; Nishiyama, H; Ogawa, O; Segawa, T; Takahashi, T; Yamamoto, S1
Bajorin, DF; Bochner, BH; Boyle, MG; Donat, SM; Galsky, MD; Herr, HW; Iasonos, A; Mironov, S; Russo, P; Scattergood, J1
Arima, K; Onishi, T; Soga, N; Sugimura, Y1
Baba, S; Irie, A; Iwamura, M; Matsumoto, K; Okazaki, M; Satoh, T1
Armstead, B; Malkowicz, SB; Ramchandani, P; Tonkonow, B; Vaughn, DJ; Wein, A; Zoltick, B1
Bajorin, DF; Hilton, S; Kelly, WK; Mazumdar, M; McCaffrey, JA; Sadan, S; Scher, HI1
Armstead, B; Fox, K; Holroyde, C; Malkowicz, SB; Mick, R; Ramchandani, P; Vaughn, DJ; Wein, A; Zoltick, B1
Du, W; Flaherty, L; Hussain, M; Redman, BG; Smith, DC1
Bajorin, DF; Herr, H; Higgins, G; Hilton, S; Kelly, WK; Mazumdar, M; McCaffrey, JA; Scher, HI; Spicer, J1
Engelholm, SA; Kamby, C; Lund, B; Sengeløv, L1
de Boer, M; de Wit, R; Kerger, J; Kruit, WH; Stoter, G; Verweij, J1
Bihrle, R; Collins, M; Finch, DE; Foster, RS; Fox, S; Roth, BJ; Sweeney, CJ; Williams, SD1
Anagnostopoulos, A; Aravantinos, G; Bakoyannis, C; Bamias, A; Deliveliotis, C; Dimopoulos, MA; Fountzilas, G; Georgoulias, V; Giannopoulos, A; Karayannis, A; Kosmidis, P; Kyriakakis, Z; Moulopoulos, LA; Pantazopoulos, D; Papadimitriou, C; Varkarakis, I; Zervas, A1
Bajorin, DF; Boyle, MG; Dodd, PM; Herr, H; Hilton, S; Icasiano, E; Kelly, WK; Mazumdar, M; McCaffrey, JA1
Cohen, MB; Dreicer, R; Hatfield, AK; Manola, J; Roth, BJ; Wilding, G1
Bajorin, DF; Dodd, PM; Herr, H; Higgins, G; Hilton, S; Icasiano, E; Kelly, WK; Mazumdar, M; McCaffrey, JA; Scher, HI1
Crawford, ED; Eastham, JA; Gross, HM; Hammond, N; Lew, D; Petrylak, DP; Redman, BG; Small, EJ1
Burris, HS; Greco, FA; Hainsworth, JD; Meluch, AA1
Bajorin, DF1
Albanell, J; Banús, JM; Baselga, J; Bastús, R; Batiste-Alentorn, E; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Diaz-Rubio, E; Font, A; Gallardo, E; González-Larriba, JL; Guillem, V; López-Brea, M; Nogué, M; Paz-Ares, L; Sáenz, A1
Börgermann, C; Krege, S; Otto, T; Rembrink, V; Rübben, H1
Carles, J; Climent, MA; Garcia del Muro, X; Germá, JR; Gumá, J; Marcuello, E; Maroto, P; Parra, MS; Paz-Ares, L; Tisaire, JL1

Reviews

7 review(s) available for paclitaxel and Cancer of the Urinary Tract

ArticleYear
Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 50, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blood Platelet Disorders; Cisplatin; Databases, Factual; Deoxycytidine; Disease-Free Survival; Doxorubicin; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Urologic Neoplasms

2018
Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
    Current opinion in supportive and palliative care, 2008, Volume: 2, Issue:3

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urologic Neoplasms; Urothelium

2008
[Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Salvage Therapy; Urologic Neoplasms; Urothelium

2011
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
    Anti-cancer drugs, 2012, Volume: 23, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kidney; Kidney Function Tests; Neoplasm Invasiveness; Paclitaxel; Randomized Controlled Trials as Topic; Urologic Neoplasms; Urothelium

2012
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:6 Suppl 6

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Taxoids; Urologic Neoplasms

2002
[The second-line chemotherapy for urological cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Male; Methotrexate; Paclitaxel; Survival Rate; Testicular Neoplasms; Treatment Outcome; Urologic Neoplasms; Vinblastine

2005
Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms

2000

Trials

47 trial(s) available for paclitaxel and Cancer of the Urinary Tract

ArticleYear
Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    International journal of clinical oncology, 2020, Volume: 25, Issue:1

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Docetaxel; Female; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine

2020
Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma.
    Anticancer research, 2020, Volume: 40, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms

2020
Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jun-01, Volume: 35, Issue:16

    Topics: Administration, Oral; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pyrimidines; Sulfonamides; Survival Rate; Urologic Neoplasms

2017
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 06-01, Volume: 30, Issue:6

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Response Evaluation Criteria in Solid Tumors; Survival Rate; Urologic Neoplasms; Vinblastine

2019
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
    Investigational new drugs, 2014, Volume: 32, Issue:1

    Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Demography; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium

2014
Second-Line Treatment of Advanced Urothelial Cancer with Paclitaxel and Everolimus in a German Phase II Trial (AUO Trial AB 35/09).
    Oncology, 2015, Volume: 89, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Everolimus; Female; Germany; Humans; Male; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome; Urologic Neoplasms; Urothelium

2015
Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.
    Urology, 2016, Volume: 89

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney; Male; Middle Aged; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Urologic Neoplasms

2016
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrimidines; Sulfonamides; Survival Analysis; Treatment Outcome; Urologic Neoplasms

2016
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
    The New England journal of medicine, 2017, 03-16, Volume: 376, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Platinum Compounds; Programmed Cell Death 1 Receptor; Survival Analysis; Taxoids; Urologic Neoplasms; Urothelium; Vinblastine

2017
In vivo evaluation of intravesical paclitaxel and combined bcl-xL antisense oligodeoxynucleotide treatment for orthotopic urothelial carcinoma.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:5

    Topics: Administration, Intravesical; Animals; Antineoplastic Agents, Phytogenic; bcl-X Protein; Carcinoma; Combined Modality Therapy; Disease Models, Animal; Humans; Kidney; Oligonucleotides, Antisense; Paclitaxel; Rats; Rats, Nude; Urinary Bladder Neoplasms; Urologic Neoplasms

2009
Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study.
    Medical oncology (Northwood, London, England), 2011, Volume: 28 Suppl 1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Urologic Neoplasms

2011
Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
    European urology, 2011, Volume: 60, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Decision Support Techniques; Deoxycytidine; Female; Gemcitabine; Germany; Hemoglobins; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Patient Selection; Regression Analysis; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine

2011
Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine

2011
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Investigational new drugs, 2012, Volume: 30, Issue:5

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Micelles; Middle Aged; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Urologic Neoplasms

2012
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hemorrhage; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium

2012
Intermittent chemotherapy is a treatment choice for advanced urothelial cancer.
    Oncology, 2012, Volume: 83, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Serum Albumin; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium

2012
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
    Cancer, 2002, Aug-15, Volume: 95, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium

2002
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
    American journal of clinical oncology, 2002, Volume: 25, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms

2002
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
    Cancer, 2003, Jun-01, Volume: 97, Issue:11

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms; Urothelium

2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
    Cancer, 2004, Jan-01, Volume: 100, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Urologic Neoplasms

2004
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Cancer, 2004, Apr-15, Volume: 100, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Vinblastine

2004
A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
    Cancer investigation, 2004, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hyperglycemia; Life Tables; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium

2004
Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer.
    European urology, 2005, Volume: 48, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium

2005
Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients.
    European urology, 2005, Volume: 48, Issue:5

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Drug Therapy, Combination; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome; Urologic Neoplasms

2005
Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study.
    Cancer, 2005, Oct-15, Volume: 104, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Urologic Neoplasms

2005
Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Salvage Therapy; Treatment Outcome; Urologic Neoplasms

2006
Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:2

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms; Urothelium

2006
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract.
    Urology, 2007, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Paclitaxel; Prospective Studies; Risk Assessment; Survival Rate; Urologic Neoplasms

2007
Paclitaxel Carboplatin chemotherapy as a second-line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases.
    International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:9

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Female; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Quality of Life; Salvage Therapy; Treatment Outcome; Urologic Neoplasms

2007
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2007, Volume: 14, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine

2007
Phase I trial of paclitaxel/carboplatin in advanced carcinoma of the urothelium.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Female; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms; Urothelium

1997
Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Docetaxel; Drug Hypersensitivity; Female; Humans; Male; Middle Aged; Paclitaxel; Remission Induction; Survival Analysis; Taxoids; Urologic Neoplasms

1997
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Urologic Neoplasms

1998
Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms

1998
Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Middle Aged; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Urologic Neoplasms

1998
Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:10

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms

1998
Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
    British journal of cancer, 1998, Volume: 78, Issue:10

    Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Edema; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urologic Neoplasms

1998
A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium.
    Cancer, 1999, Aug-01, Volume: 86, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle Aged; Paclitaxel; Survival Analysis; Urologic Neoplasms; Urothelium

1999
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Greece; Humans; Linear Models; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Remission Induction; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium

1999
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Middle Aged; Nausea; Paclitaxel; Remission Induction; Urologic Neoplasms; Vomiting

2000
Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Female; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium

2000
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Cancer, 2000, Apr-01, Volume: 88, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Feasibility Studies; Female; Humans; Ifosfamide; Male; Middle Aged; Paclitaxel; Taxoids; Time Factors; Urologic Neoplasms

2000
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urologic Neoplasms

2000
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Vinblastine

2000
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Sep-15, Volume: 18, Issue:18

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Urologic Neoplasms

2000
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study.
    The Journal of urology, 2001, Volume: 165, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Treatment Failure; Urologic Neoplasms

2001
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
    British journal of cancer, 2002, Feb-01, Volume: 86, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium

2002

Other Studies

14 other study(ies) available for paclitaxel and Cancer of the Urinary Tract

ArticleYear
Mast cells activation and high blood tryptase levels due to paclitaxel administration. Is Cremophor EL the culprit?: A case report.
    Medicine, 2020, Oct-23, Volume: 99, Issue:43

    Topics: Aged; Drug Hypersensitivity; Glycerol; Humans; Male; Mast Cells; Paclitaxel; Tryptases; Urologic Neoplasms

2020
Reply to M. Horiguchi et al.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 10-10, Volume: 35, Issue:29

    Topics: Humans; Indazoles; Paclitaxel; Pyrimidines; Sulfonamides; Urologic Neoplasms

2017
Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 10-10, Volume: 35, Issue:29

    Topics: Humans; Indazoles; Paclitaxel; Pyrimidines; Sulfonamides; Urologic Neoplasms

2017
The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
    Acta medica Okayama, 2018, Volume: 72, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms

2018
Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
    International journal of clinical oncology, 2018, Volume: 23, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Urologic Neoplasms

2018
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
    Current oncology (Toronto, Ont.), 2019, Volume: 26, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium

2019
[A case of peritoneal carcinomatosis due to recurrence of primary adenocarcinoma of the ureter treated with weekly paclitaxel].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Urologic Neoplasms

2014
Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome; Urologic Neoplasms

2015
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:3

    Topics: Aged; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Paclitaxel; Piperidines; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium

2015
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    European urology, 2016, Volume: 69, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium

2016
Quality of life in patients with cisplatin-resistant urothelial cancer: Typical ailments and effect of paclitaxel-based salvage therapy.
    Urologic oncology, 2016, Volume: 34, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Quality of Life; Salvage Therapy; Urologic Neoplasms; Urothelium

2016
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:3

    Topics: Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pain; Pain Measurement; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms; Urothelium

2012
Combining paclitaxel and lapatinib as second-line treatment for patients with metastatic transitional cell carcinoma: a case series.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Humans; Lapatinib; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Quinazolines; Salvage Therapy; Urinary Bladder Neoplasms; Urologic Neoplasms

2012
[Paclitaxel, ifosfamide, nedaplatin (TIN) for patients with metastatic urothelial cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Paclitaxel; Survival Rate; Thrombocytopenia; Urologic Neoplasms

2004